DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
National Institutes of Health Clinical Center (CC)
Enterome
University of Avignon
Barts & The London NHS Trust
Asan Medical Center
Instituto do Cancer do Estado de São Paulo
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Yale University
Molecular Insight Pharmaceuticals, Inc.
Vanderbilt-Ingram Cancer Center